Evidence map›Paper›PMID 38296301›Full record

Trial reportBMJ open2024

Cost-effectiveness of a primary healthcare intervention to treat male lower urinary tract symptoms: the TRIUMPH cluster randomised controlled trial.

Madeleine Cochrane, Marcus J Drake, Jo Worthington, Jessica Frost, Nikki Cotterill, Mandy Fader, Lucy McGeagh, Hashim Hashim, Athene Lane, Margaret Macaulay and 8 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Self-management of male urinary symptoms: qualitative findings from a primary care trial.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026
    Trial
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Madeleine CochranePopulation Health Sciences, University of Bristol, Bristol, UK madeleine.cochrane@bristol.ac.uk.ORCID 0000-0003-1856-3293
Marcus J DrakeDepartment of Surgery & Cancer, Imperial College London, London, UK.
Jo WorthingtonPopulation Health Sciences, University of Bristol, Bristol, UK.
Jessica FrostPopulation Health Sciences, University of Bristol, Bristol, UK.
Nikki CotterillDepartment of Nursing & Midwifery, University of the West of England, Bristol, UK.
Mandy FaderSchool of Health Sciences, University of Southampton, Southampton, UK.
Lucy McGeaghFaculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK.ORCID 0000-0002-9226-5115
Hashim HashimBristol Urological Institute, North Bristol NHS Trust Southmead Hospital, Bristol, UK.
Athene LanePopulation Health Sciences, University of Bristol, Bristol, UK.
Margaret MacaulayFaculty of Health Sciences, University of Southampton, Southampton, UK.
Stephanie MacNeillPopulation Health Sciences, University of Bristol, Bristol, UK.
Jonathan ReesBrockway Medical Centre, Bristol, UK.
Matthew J RiddPopulation Health Sciences, University of Bristol, Bristol, UK.ORCID 0000-0002-7954-8823
Luke A RoblesNIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK.ORCID 0000-0003-2882-9868
Emily SandersonPopulation Health Sciences, University of Bristol, Bristol, UK.
Gordon TaylorPublic and Patient Involvement Representative, Bristol, UK.
Jodi TaylorPopulation Health Sciences, University of Bristol, Bristol, UK.
Sian NoblePopulation Health Sciences, University of Bristol, Bristol, UK.
University of Bristol · GBAt Bristol · GBFaculty of Public Health · GBImperial College London · GBNorth Bristol NHS Trust · GBOxford Brookes University · GBUniversity of Southampton · GBUniversity of the West of England · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo estimate the cost-effectiveness of a primary care intervention for male lower urinary tract symptoms (LUTS) compared with usual care.

designEconomic evaluation alongside a cluster randomised controlled trial from a UK National Health Service (NHS) perspective with a 12-month time horizon.

settingThirty NHS general practice sites in England.

participants1077 men aged 18 or older identified in primary care with bothersome LUTS.

interventionsA standardised and manualised intervention for the treatment of bothersome LUTS was compared with usual care. The intervention group (n=524) received a standardised information booklet with guidance on conservative treatment for LUTS, urinary symptom assessment and follow-up contacts for 12 weeks. The usual care group (n=553) followed local guidelines between general practice sites. MEASURES: Resource use was obtained from electronic health records, trial staff and participants, and valued using UK reference costs. Quality-adjusted life-years (QALYs) were calculated from the EQ-5D-5L questionnaire. Adjusted mean differences in costs and QALYs and incremental net monetary benefit were estimated.

results866 of 1077 (80.4%) participants had complete data and were included in the base-case analysis. Over the 12-month follow-up period, intervention and usual care arms had similar mean adjusted costs and QALYs. Mean differences were lower in the intervention arm for adjusted costs -£29.99 (95% CI -£109.84 to £22.63) while higher in the intervention arm for adjusted QALYs 0.001 (95% CI -0.011 to 0.014). The incremental net monetary benefit statistic was £48.01 (95% CI -£225.83 to £321.85) at the National Institute for Health and Care Excellence UK threshold of £20 000 per QALY. The cost-effectiveness acceptability curve showed a 63% probability of the intervention arm being cost-effective at this threshold.

conclusionsCosts and QALYs were similar between the two arms at 12 months follow-up. This indicates that the intervention can be implemented in general practice at neutral cost. TRIAL REGISTRATION NUMBER: ISRCTN11669964.

Indexed as

Lower Urinary Tract SymptomsState MedicineCost-Benefit AnalysisEnglandHumansMalePrimary Health CareQuality-Adjusted Life YearsQuality of LifeHEALTH ECONOMICSPrimary Health CareUROLOGY

Identifiers

PMID38296301
PMCPMC10828877
OpenAlexW4391405461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.